Utilidad de la interleukina-6 y de la proteína C reactiva ultrasensible como marcadores pronósticos en pacientes ambulatorios con insuficiencia cardíaca y fracción de eyección reducida

  1. Chirino Navarta, Daniel Agustín; Servicio de Cardiología de la Unidad Asistencial Por Más Salud Dr. César Milstein, Ciudad Autónoma de Buenos Aires; Servicio de Cardiología del Sanatorio Franchín, Ciudad Autónoma de Buenos Aires; 1
  2. Trejo, Graciela 2
  3. Leonardi, Mariela Susana 2
  4. Fossati, María Pía 3
  5. Gurfinkel, Mirta 4
  6. Tellechea, Francisco 5
  7. Rodriguez Vazquez, María Luisa 6
  8. Dizeo, Claudio 7
  1. 1 Servicio de Cardiología de la Unidad Asistencial Por Más Salud Dr. César Milstein, Ciudad Autónoma de Buenos Aires (Argentina)
  2. 2 Coordinadora Unidad Coronaria, Hospital César Milstein
  3. 3 Laboratorio Central, Hospital César Milstein
  4. 4 Jefa Laboratorio Central, Hospital César Milstein
  5. 5 Medico de planta, Servicio Cardiología, Hospital César Milstein
  6. 6 Medica de planta Servicio Cardiología, Hospital César Milstein
  7. 7 Jefe del Servicio de Cardiología, Hospital César Milstein
Mostrar afiliacións +
Revista:
Revista Argentina de Cardiología (RAC)

Ano de publicación: 2020

Volume: 88

Número: 3

Páxinas: 194-200

Tipo: Artigo

DOI: 10.7775/AJC.88.3.17251 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Resumo

Purpose: The aim of this study was to assess whether interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP)associated with B-type natriuretic peptide (BNP) are independent markers of adverse events in outpatients with heart failureand reduced ejection fraction (HFrEF).Methods: Patients older than 65 years of age with HFrEF who were followed-up on an outpatient basis were prospectivelyincluded. Baseline BNP, IL-6 and hsCRP levels were assessed. Patients with HF after recent myocardial infarction (<6 months),and recent hospitalization (<3 months) due to a condition that could increase inflammatory markers were excluded fromthe analysis. The composite endpoint was all-cause mortality and hospitalization for decompensated heart failure (DHF).Results: A total of 130 patients aged 75 ± 5 years and with EF of 33 ± 11% were included in the study. The composite endpointwas observed in 31.5% (n=41) of patients during a follow-up period of 450 ± 210 days. In the multivariate analysis, elevatedBNP (>442 pg/ml) and elevated IL-6 (>7.2 pg/ml) were independent predictors of the primary endpoint [HR 2.60 (95% CI1.14-5.9), p=0.02 and HR 2.49 (95% CI 1.08-5.7), p=0.03, respectively], but not hsCRP >6.9 mg/l, p=0.2. IL-6 presented anarea under the ROC curve (AUC) of 0.70, BNP 0.73 and hsPCR 0.63, without significant differences between them.Conclusions: BNP and IL-6 were independent markers of the composite endpoint, but not CRP. The discrimination ability ofIL-6 and BNP was moderate.

Referencias bibliográficas

  • Chioncel O, Lainscak M, Seferovic P, Manker S, Crespo-Leiro M, Harjola VP et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574-85. https://doi.org/10.1002/ejhf.813
  • Curtis LH, Whellan DJ, Hammill BG, Hernandez AF, Anstrom KJ, Shea AM, et al. Incidence and Prevalence of Heart Failure in Elderly Persons, 1994-2003. Arch Intern Med 2008;168:418–24. https://doi.org/10.1001/archinternmed.2007.80
  • Dávila DF, Núñez TJ, Odreman R, de Dávila CAD. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 2005;101:343-6. https://doi.org/10.1016/j.ijcard.2004.08.023
  • Kaplinsky E. Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis 2016;7:278–90. https://doi.org/10.1177/2040622316665350
  • Anker SD, von Haehling S.Inflammatory mediators in chronic heart failure: an overview. Heart 2004;90:464-70. https://doi.org/10.1136/hrt.2002.007005
  • Kanda T and Takahashi T. Interleukin-6 and Cardiovascular Diseases. Jpn Heart J 2004;45:183-93. https://doi.org/ 10.1536/jhj.45.183
  • Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 2003;14:515-21. https://doi.org/10.1097/00001721-200309000-00001
  • Jug, B, Salobir N, Vene M, Šebeátjen M, Šabovič M and Keber I. Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels 2009;24;271–6. https://doi.org/ 10.1007/s00380-008-1111-4
  • Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira AJ, et al. Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review. J Card Fail 2009;15:256–66. https://doi.org/10.1016/j.cardfail.2008.10.030
  • Marino FA, Barisani JL, Thierer J, Liniado G, Pereiro SM, Francesia A, et al. Consenso de insuficiencia cardíaca crónica. Sociedad Argentina de Cardiología. Rev Arg Cardiol 2016;84(supl 3):1-50.
  • Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129-200. https://doi.org/10.1093/eurheartj/ehw128
  • Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie AC, et al. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail 2016;18:1491-8. https://doi.org/10.1002/ejhf.543
  • Ueno A, Murasaki K, Hagiwara N, Kasanuki H. Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy. Heart Vessel 2007;22:316-21.https://doi.org/10.1007/s00380-007-0977-x
  • Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai DT, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391–8 https://doi.org/10.1016/S0735-1097(97)00494-4
  • Torre-Amione G, Kapadia S, Benedict CR, Oral H, Young JB, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1998;27:1201-6. https://doi.org/10.1016/0735-1097(95)00589-7
  • Deswal A, Petersen NJ, Feldman AM, Young JB and M. DL, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-9. https://doi.org/10.1161/01.CIR.103.16.2055
  • Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7. https://doi.org/10.1161/01.CIR.102.25.3060
  • Chin AD, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003;33:941-8. https://doi.org/10.1046/j.1365-2362.2003.01252.x
  • Gwechenberger M, Hülsmann M, Berger R, Graf S, Springer C, Stanek B, et al. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant 2004;23:839-44. https://doi.org/10.1016/j.healun.2003.07.023
  • Boffa GM, Zaninotto M, Sartor R, Mion M, Berton A, Pasqualetto C, et al. Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure: a head-to-head clinical comparison with B type natriuretic peptide. J Cardiovasc Med 2009;10:758-64. https://doi.org/10.2459/JCM.0b013e32832ce8e2
  • Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail 2019;21:965-73. https://doi.org/10.1002/ejhf.1482
  • Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 2017;19:627-34. https://doi.org/10.1002/ejhf.785
  • Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115e26. https://doi.org/10.1016/S00028703(99)70266-8
  • Strandberg TE, Tilvis RS.. Arter Thromb Vasc Biol 2000;20:1057e60.https://doi.org/10.1161/01.ATV.20.4.1057
  • Ridker. PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J 1998;1:91–3. https://doi.org/10.1053/euhj.1997.0604
  • Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Signorini S, et al. C-reactive protein in heart failure: Prognostic value and the effect of valsartan. Circulation 2005;112:1428-34.https://doi.org/10.1161/CIRCULATIONAHA.104.508465
  • Chirinos JA, Zambrano JP, Chakko S, Schob A, Veerani A, Perez GO, et al. Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol 2005;95: 88-90. https://doi.org/10.1016/j.amjcard.2004.08.065
  • Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, Bauters C, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005;26:2245-50. https://doi.org/10.1093/eurheartj/ehi501
  • Windram J, Loh P, Rigby A, Hanning I, Clark A, et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 2007;153:1048-55. https://doi.org/10.1016/j.ahj.2007.03.044
Fonte de datos: Dialnet